CompletedNCT00700427
A Long Term Study of a Medication for Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Medication studyAges 18–50Multiple countries
Understand this study
Who was this study for?
Listed age limits: 18 years to 50 years.
- Listed locations
- Vienna, Austria · Bruges, Belgium and 54 more locationsSee all locations and recruitment
- Activities
- Medication and placebo comparator listed across study groups · Placebo comparator
- Compensation
- Payment and expense reimbursement have not been verified.
Study information
Study start dateJune 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 2,017
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- France, United Kingdom, Switzerland, ...
- Age range
- From 18 Years to 50 Years
- Official registry ID
- NCT00700427
- Official title
Show the full official title
Maintenance of Response After Open-Label Treatment With Atomoxetine Hydrochloride in Adult Outpatients With Attention-Deficit/Hyperactivity Disorder (ADHD): A Placebo-Controlled, Randomized Withdrawal Study
Recruitment & locations
CompletedVienna, Austria · Bruges, Belgium · Kortenberg, Belgium
53 more locations
- Liège, Belgium
- Mechelen, Belgium
- Uccle, Belgium
- Helsinki, Finland
- Tampere, Finland
- Turku, Finland
- Bordeaux, France
- Douai, France
- Marseille, France
- Montpellier, France
- Nice, France
- Orvault, France
- Ahrensburg, Germany
- Berlin, Germany
- Bochum, Germany
- Ellwangen, Germany
- Essen, Germany
- Freiburg im Breisgau, Germany
- Fulda, Germany
- Hadamar, Germany
- Hagen, Germany
- Hamburg, Germany
- Hanover, Germany
- Homburg, Germany
- Leipzig, Germany
- Ludwigshafen, Germany
- Mainz, Germany
- Mannheim, Germany
- Munich, Germany
- Würzburg, Germany
- Coppito, Italy
- Milan, Italy
- San Donà di Piave, Italy
- Amersfoort, Netherlands
- Flushing, Netherlands
- Hengelo, Netherlands
- Nijmegen, Netherlands
- Tilburg, Netherlands
- Cascais, Portugal
- Coimbra, Portugal
- Alcorcón, Spain
- Barcelona, Spain
- Madrid, Spain
- Pamplona, Spain
- Zamora, Spain
- Luleå, Sweden
- Lund, Sweden
- Malmö, Sweden
- Vaxjo, Sweden
- Lausanne, Switzerland
- Brighton, United Kingdom
- Storrington, United Kingdom
- London, United Kingdom
Questions about this study
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Did this study involve medication?
Yes. The study involved medication, including atomoxetine hydrochloride and Placebo.
Who was this study for?
Listed age limits: 18 years to 50 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedEUCTR 2010-021533-31
A 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-onset ADHD
Belgium, Denmark, Germany, + 2 others
CompletedEUCTR 2011-000210-19
A 6-month, open-label extension to a 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-on...
Belgium, Denmark, Germany, + 1 other
CompletedEUCTR 2005-003002-28
A 7 week multicenter, double-blind, randomized, placebo-controlled cross-over evaluation of the efficacy and safety of a modified-release oral dosage form of methylphenidate-HCl, Ritalin LA® (20 mg...
Germany